Arcadia Biosciences Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arcadia Biosciences stock.
View analyst ratings for Arcadia Biosciences or view top-rated stocks.

Wall Street analysts have given Arcadia Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arcadia Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Arcadia Biosciences saw a increase in short interest in the month of February. As of February 12th, there was short interest totaling 2,830,000 shares, an increase of 44.4% from the January 28th total of 1,960,000 shares. Based on an average trading volume of 1,470,000 shares, the days-to-cover ratio is currently 1.9 days.
View Arcadia Biosciences' Short Interest.

Arcadia Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for Arcadia Biosciences.

Arcadia Biosciences, Inc. (NASDAQ:RKDA) issued its quarterly earnings results on Tuesday, November, 17th. The basic materials company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.06. The basic materials company earned $0.31 million during the quarter, compared to analyst estimates of $0.97 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 177.69% and a negative net margin of 1,499.85%.
View Arcadia Biosciences' earnings history.

Arcadia Biosciences' stock was trading at $3.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RKDA shares have decreased by 15.1% and is now trading at $2.69.
View which stocks have been most impacted by COVID-19.

Arcadia Biosciences shares reverse split on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split.

2 analysts have issued 1-year target prices for Arcadia Biosciences' shares. Their forecasts range from $6.00 to $16.00. On average, they expect Arcadia Biosciences' share price to reach $11.00 in the next year. This suggests a possible upside of 308.9% from the stock's current price.
View analysts' price targets for Arcadia Biosciences or view top-rated stocks among Wall Street analysts.

1 employees have rated Arcadia Biosciences CEO Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among Arcadia Biosciences' employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Arcadia Biosciences include Alico (ALCO), Novus Capital (NOVS), S&W Seed (SANW), Origin Agritech (SEED), China Liaoning Dingxu Ecological Agriculture Development (CLAD), Hawaiian Macadamia Nut Orchards (NNUTU), Margo Caribe (MRGO), YaSheng Group (HERB), Scheid Vineyards (SVIN), Shineco (TYHT), Yew Bio-Pharm Group (YEWB) and Two Rivers Water & Farming (TURV).
View all of RKDA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), Cannabics Pharmaceuticals (CNBX) and Enerplus (ERF).

(RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO.

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

Arcadia Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include GSA Capital Partners LLP (1.18%), Wells Fargo & Company MN (0.29%) and LPL Financial LLC (0.25%). Company insiders that own Arcadia Biosciences stock include Kevin Comcowich, Lilian Shackelford Murray, Matthew T Plavan and Sarah Reiter.
View institutional ownership trends for Arcadia Biosciences.

RKDA stock was acquired by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Wells Fargo & Company MN, and LPL Financial LLC. Company insiders that have bought Arcadia Biosciences stock in the last two years include Kevin Comcowich, Lilian Shackelford Murray, Matthew T Plavan, and Sarah Reiter.
View insider buying and selling activity for Arcadia Biosciences or or view top insider-buying stocks.

Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RKDA stock can currently be purchased for approximately $2.69.

Arcadia Biosciences has a market capitalization of $57.37 million and generates $1.17 million in revenue each year. The basic materials company earns $-28,810,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis.

Arcadia Biosciences employs 41 workers across the globe.

The official website for Arcadia Biosciences is www.arcadiabio.com.

Arcadia Biosciences is headquartered at 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018.

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at 530-756-7077 or via email at [email protected]